Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Epsins 1 and 2 promote NEMO linear ubiquitination via LUBAC to drive breast cancer development
Kai Song, … , Yibin Kang, Hong Chen
Kai Song, … , Yibin Kang, Hong Chen
Published September 22, 2020
Citation Information: J Clin Invest. 2021;131(1):e129374. https://doi.org/10.1172/JCI129374.
View: Text | PDF
Research Article Cell biology Oncology

Epsins 1 and 2 promote NEMO linear ubiquitination via LUBAC to drive breast cancer development

  • Text
  • PDF
Abstract

Estrogen receptor–negative (ER-negative) breast cancer is thought to be more malignant and devastating than ER-positive breast cancer. ER-negative breast cancer exhibits elevated NF-κB activity, but how this abnormally high NF-κB activity is maintained is poorly understood. The importance of linear ubiquitination, which is generated by the linear ubiquitin chain assembly complex (LUBAC), is increasingly appreciated in NF-κB signaling, which regulates cell activation and death. Here, we showed that epsin proteins, a family of ubiquitin-binding endocytic adaptors, interacted with LUBAC via its ubiquitin-interacting motif and bound LUBAC’s bona fide substrate NEMO via its N-terminal homolog (ENTH) domain. Furthermore, epsins promoted NF-κB essential modulator (NEMO) linear ubiquitination and served as scaffolds for recruiting other components of the IκB kinase (IKK) complex, resulting in the heightened IKK activation and sustained NF-κB signaling essential for the development of ER-negative breast cancer. Heightened epsin levels in ER-negative human breast cancer are associated with poor relapse-free survival. We showed that transgenic and pharmacological approaches eliminating epsins potently impeded breast cancer development in both spontaneous and patient-derived xenograft breast cancer mouse models. Our findings established the pivotal role epsins played in promoting breast cancer. Thus, targeting epsins may represent a strategy to restrain NF-κB signaling and provide an important perspective into ER-negative breast cancer treatment.

Authors

Kai Song, Xiaofeng Cai, Yunzhou Dong, Hao Wu, Yong Wei, Uma T. Shankavaram, Kui Cui, Yang Lee, Bo Zhu, Sudarshan Bhattacharjee, Beibei Wang, Kun Zhang, Aiyun Wen, Scott Wong, Lili Yu, Lijun Xia, Alana L. Welm, Diane R. Bielenberg, Kevin A. Camphausen, Yibin Kang, Hong Chen

×

Figure 3

Recruitment of epsin to TNFR1 complex in response to TNF-α stimulus and epsin interacts with LUBAC and its substrates in a UIM-dependent manner.

Options: View larger image (or click on image) Download as PowerPoint
Recruitment of epsin to TNFR1 complex in response to TNF-α stimulus and ...
(A) Mouse primary fibroblasts (mFibroblasts) were stimulated with Flag–TNF-α (1 μg/mL) for 5 minutes, lysed, and pulled down using anti-Flag M2 affinity gel at 4°C for 16 hours, following by Western blot analysis of epsin, NEMO, and components of TNF receptor signaling complex (TNF-RSC). (B) Western blot analysis of anti-HA IP in 293T cells cotransfected with Flag-tagged RIP1 (or K337R mutant RIP1) and HA–epsin 1 or HA–epsin 1 ΔUIM after TNF-α stimulation (20 ng/mL) for 5 minutes. (C) Western blot analysis of linear K48-linked or K63-linked tetraubiquitin (tetraUb) pulled down by biotinylated scramble control peptide or epsin UIM peptide. (D) Western blot analysis of anti-Flag IP in Ctrl (generated by transfecting scrambled siRNA using lipofectamine RNAiMAX) or LUBAC KD (generated by transfecting siRNA against HOIP and HOIL-1L, respectively) 293T cells, which were cotransfected with Flag–WT RIP1 and HA–epsin 1 after TNF-α stimulation (20 ng/mL) for 5 minutes. (E–G) Western blot analysis of anti-Flag IP in 293T cells cotransfected with Flag-NEMO (E), Flag-HOIP (F), or Flag–HOIL-1L (G), and HA–epsin 1 or HA–epsin 1 ΔUIM after TNF-α stimulation (20 ng/mL) for 5 minutes. Results are representative of 3 independent experiments (A–G). See also Supplemental Figure 3.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts